| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CRO服务(元) | 13,881,945.18 | - | 8,555,182.02 | - | 7,620,771.42 |
| 靶点及因子类蛋白(元) | 45,442,037.21 | 80,675,065.50 | 41,846,420.14 | 64,593,303.09 | 29,129,077.19 |
| 酶及试剂(元) | 17,360,069.41 | 41,951,600.28 | 18,474,457.18 | 41,719,193.17 | 19,769,434.84 |
| 重组抗体(元) | 1,767,769.63 | 3,352,607.54 | 1,928,029.50 | 5,241,486.54 | 3,086,286.36 |
| 技术服务(元) | - | 20,088,608.73 | - | 15,848,872.88 | - |
| 营业成本(元) | |||||
| CRO服务(元) | 10,305,304.42 | - | 8,155,952.53 | - | 5,101,127.77 |
| 靶点及因子类蛋白(元) | 9,410,412.40 | 18,529,309.84 | 9,452,918.98 | 18,305,939.13 | 8,608,361.97 |
| 酶及试剂(元) | 4,431,507.51 | 11,842,131.37 | 6,483,222.66 | 15,895,037.38 | 7,640,946.91 |
| 重组抗体(元) | 334,491.83 | 861,140.83 | 344,766.55 | 1,200,478.36 | 480,817.96 |
| 技术服务(元) | - | 16,807,199.49 | - | 12,492,289.84 | - |
| 毛利(元) | |||||
| CRO服务(元) | 3,576,640.76 | - | 399,229.49 | - | 2,519,643.65 |
| 靶点及因子类蛋白(元) | 36,031,624.81 | 62,145,755.66 | 32,393,501.16 | 46,287,363.96 | 20,520,715.22 |
| 酶及试剂(元) | 12,928,561.90 | 30,109,468.91 | 11,991,234.52 | 25,824,155.79 | 12,128,487.93 |
| 重组抗体(元) | 1,433,277.80 | 2,491,466.71 | 1,583,262.95 | 4,041,008.18 | 2,605,468.40 |
| 技术服务(元) | - | 3,281,409.24 | - | 3,356,583.04 | - |
| 毛利率(%) | |||||
| CRO服务(%) | 25.76 | - | 4.67 | - | 33.06 |
| 靶点及因子类蛋白(%) | 79.29 | 77.03 | 77.41 | 71.66 | 70.45 |
| 酶及试剂(%) | 74.47 | 71.77 | 64.91 | 61.90 | 61.35 |
| 重组抗体(%) | 81.08 | 74.31 | 82.12 | 77.10 | 84.42 |
| 技术服务(%) | - | 16.33 | - | 21.18 | - |
| 收入构成(%) | |||||
| CRO服务(%) | 17.69 | - | 12.08 | - | 12.79 |
| 靶点及因子类蛋白(%) | 57.92 | 55.23 | 59.10 | 50.70 | 48.87 |
| 酶及试剂(%) | 22.13 | 28.72 | 26.09 | 32.75 | 33.17 |
| 重组抗体(%) | 2.25 | 2.30 | 2.72 | 4.11 | 5.18 |
| 技术服务(%) | - | 13.75 | - | 12.44 | - |
| 毛利构成(%) | |||||
| CRO服务(%) | 6.63 | - | 0.86 | - | 6.67 |
| 靶点及因子类蛋白(%) | 66.76 | 63.40 | 69.86 | 58.22 | 54.32 |
| 酶及试剂(%) | 23.96 | 30.72 | 25.86 | 32.48 | 32.11 |
| 重组抗体(%) | 2.66 | 2.54 | 3.41 | 5.08 | 6.90 |
| 技术服务(%) | - | 3.35 | - | 4.22 | - |